Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Oct;72(4):917–921. doi: 10.1038/bjc.1995.433

DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?

E Smitskamp-Wilms 1, G Giaccone 1, H M Pinedo 1, B F van der Laan 1, G J Peters 1
PMCID: PMC2034035  PMID: 7547240

Abstract

DT-diaphorase (DTD) is an important enzyme for the bioreductive activation of the new alkylating indoloquinone EO9. In preclinical studies, EO9 has shown selective anti-tumour activity against solid tumours and under hypoxic conditions. The levels of three reductive enzymes have been determined in three types of human solid tumours, together with corresponding normal tissues and normal liver. DTD enzyme activities were measured in tumour extracts using 2,6-dichlorophenolindophenol (DCPIP) and NADH as substrates; cytochrome P450 reductase or cytochrome b5 reductase activities were assessed with cytochrome c and NADPH or NADH respectively. DTD activity was highest in non-small-cell lung (NSCLC)-tumours (mean 123 nmol DCPIP min-1 mg-1), followed by colon carcinoma (mean 75 nmol min-1 mg-1) and squamous cell carcinoma of the head and neck (6-fold lower than NSCLC). DTD activity was very low in normal liver and normal lung (4-6 nmol min-1 mg-1), while the levels in normal colon mucosa or normal mucosa of the head and neck region were in the same range as the corresponding tumours. The levels of the two other reductive enzymes, cytochrome P450 reductase (CP450R) and cytochrome b5 reductase (Cb5R), were 5 to 25-fold lower than those of DTD in all the tissues, except for normal liver, in which DTD was 2 to 4-fold lower. The degree of variation found for DTD (range 4-250 nmol min-1 mg-1), was not observed for these enzymes (CP450R, 0.8-7.8 nmol cytochrome c min-1 mg-1; Cb5R, 3.5-27.6 nmol min-1 mg-1).(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
917

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams G. E., Stratford I. J. Bioreductive drugs for cancer therapy: the search for tumor specificity. Int J Radiat Oncol Biol Phys. 1994 May 15;29(2):231–238. doi: 10.1016/0360-3016(94)90267-4. [DOI] [PubMed] [Google Scholar]
  2. Adams G. E., Stratford I. J., Edwards H. S., Bremner J. C., Cole S. Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9. Int J Radiat Oncol Biol Phys. 1992;22(4):717–720. doi: 10.1016/0360-3016(92)90510-o. [DOI] [PubMed] [Google Scholar]
  3. Belinsky M., Jaiswal A. K. NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev. 1993 Jun;12(2):103–117. doi: 10.1007/BF00689804. [DOI] [PubMed] [Google Scholar]
  4. Benson A. M., Hunkeler M. J., Talalay P. Increase of NAD(P)H:quinone reductase by dietary antioxidants: possible role in protection against carcinogenesis and toxicity. Proc Natl Acad Sci U S A. 1980 Sep;77(9):5216–5220. doi: 10.1073/pnas.77.9.5216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Boland M. P., Knox R. J., Roberts J. J. The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide) 1991 Mar 15-Apr 1Biochem Pharmacol. 41(6-7):867–875. doi: 10.1016/0006-2952(91)90190-g. [DOI] [PubMed] [Google Scholar]
  6. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  7. Cresteil T., Jaiswal A. K. High levels of expression of the NAD(P)H:quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin. Biochem Pharmacol. 1991 Aug 8;42(5):1021–1027. doi: 10.1016/0006-2952(91)90284-c. [DOI] [PubMed] [Google Scholar]
  8. ERNSTER L., DANIELSON L., LJUNGGREN M. DT diaphorase. I. Purification from the soluble fraction of rat-liver cytoplasm, and properties. Biochim Biophys Acta. 1962 Apr 9;58:171–188. doi: 10.1016/0006-3002(62)90997-6. [DOI] [PubMed] [Google Scholar]
  9. Eickelmann P., Ebert T., Warskulat U., Schulz W. A., Sies H. Expression of NAD(P)H:quinone oxidoreductase and glutathione S-transferases alpha and pi in human renal cell carcinoma and in kidney cancer-derived cell lines. Carcinogenesis. 1994 Feb;15(2):219–225. doi: 10.1093/carcin/15.2.219. [DOI] [PubMed] [Google Scholar]
  10. Hendriks H. R., Pizao P. E., Berger D. P., Kooistra K. L., Bibby M. C., Boven E., Dreef-van der Meulen H. C., Henrar R. E., Fiebig H. H., Double J. A. EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur J Cancer. 1993;29A(6):897–906. doi: 10.1016/s0959-8049(05)80434-4. [DOI] [PubMed] [Google Scholar]
  11. Malkinson A. M., Siegel D., Forrest G. L., Gazdar A. F., Oie H. K., Chan D. C., Bunn P. A., Mabry M., Dykes D. J., Harrison S. D. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cł. Cancer Res. 1992 Sep 1;52(17):4752–4757. [PubMed] [Google Scholar]
  12. Peters G. J., Lankelma J., Kok R. M., Noordhuis P., van Groeningen C. J., van der Wilt C. L., Meyer S., Pinedo H. M. Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. Cancer Chemother Pharmacol. 1993;31(4):269–276. doi: 10.1007/BF00685670. [DOI] [PubMed] [Google Scholar]
  13. Peters G. J., Laurensse E. J., Leyva A., Pinedo H. M. Tissue homogenization using a micro-dismembrator for the measurement of enzyme activities. Clin Chim Acta. 1986 Jul 30;158(2):193–198. doi: 10.1016/0009-8981(86)90236-6. [DOI] [PubMed] [Google Scholar]
  14. Peters G. J., van der Wilt C. L., van Groeningen C. J., Smid K., Meijer S., Pinedo H. M. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol. 1994 Oct;12(10):2035–2042. doi: 10.1200/JCO.1994.12.10.2035. [DOI] [PubMed] [Google Scholar]
  15. Plumb J. A., Gerritsen M., Milroy R., Thomson P., Workman P. Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines. Int J Radiat Oncol Biol Phys. 1994 May 15;29(2):295–299. doi: 10.1016/0360-3016(94)90278-x. [DOI] [PubMed] [Google Scholar]
  16. Plumb J. A., Gerritsen M., Workman P. DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9. Br J Cancer. 1994 Dec;70(6):1136–1143. doi: 10.1038/bjc.1994.461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Plumb J. A., Workman P. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. Int J Cancer. 1994 Jan 2;56(1):134–139. doi: 10.1002/ijc.2910560124. [DOI] [PubMed] [Google Scholar]
  18. Prochaska H. J., Talalay P. Regulatory mechanisms of monofunctional and bifunctional anticarcinogenic enzyme inducers in murine liver. Cancer Res. 1988 Sep 1;48(17):4776–4782. [PubMed] [Google Scholar]
  19. Riley R. J., Workman P. DT-diaphorase and cancer chemotherapy. Biochem Pharmacol. 1992 Apr 15;43(8):1657–1669. doi: 10.1016/0006-2952(92)90694-e. [DOI] [PubMed] [Google Scholar]
  20. Robertson N., Haigh A., Adams G. E., Stratford I. J. Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia. Eur J Cancer. 1994;30A(7):1013–1019. doi: 10.1016/0959-8049(94)90134-1. [DOI] [PubMed] [Google Scholar]
  21. Robertson N., Stratford I. J., Houlbrook S., Carmichael J., Adams G. E. The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase? Biochem Pharmacol. 1992 Aug 4;44(3):409–412. doi: 10.1016/0006-2952(92)90429-m. [DOI] [PubMed] [Google Scholar]
  22. Ross D., Siegel D., Beall H., Prakash A. S., Mulcahy R. T., Gibson N. W. DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C. Cancer Metastasis Rev. 1993 Jun;12(2):83–101. doi: 10.1007/BF00689803. [DOI] [PubMed] [Google Scholar]
  23. Schellens J. H., Planting A. S., van Acker B. A., Loos W. J., de Boer-Dennert M., van der Burg M. E., Koier I., Krediet R. T., Stoter G., Verweij J. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09. J Natl Cancer Inst. 1994 Jun 15;86(12):906–912. doi: 10.1093/jnci/86.12.906. [DOI] [PubMed] [Google Scholar]
  24. Schlager J. J., Powis G. Cytosolic NAD(P)H:(quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer. 1990 Mar 15;45(3):403–409. doi: 10.1002/ijc.2910450304. [DOI] [PubMed] [Google Scholar]
  25. Schor N. A., Cornelisse C. J. Biochemical and quantitative histochemical study of reduced pyridine nucleotide dehydrogenation by human colonic carcinomas. Cancer Res. 1983 Oct;43(10):4850–4855. [PubMed] [Google Scholar]
  26. Siegel D., Beall H., Senekowitsch C., Kasai M., Arai H., Gibson N. W., Ross D. Bioreductive activation of mitomycin C by DT-diaphorase. Biochemistry. 1992 Sep 1;31(34):7879–7885. doi: 10.1021/bi00149a019. [DOI] [PubMed] [Google Scholar]
  27. Siegel D., Gibson N. W., Preusch P. C., Ross D. Metabolism of diaziquone by NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase): role in diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res. 1990 Nov 15;50(22):7293–7300. [PubMed] [Google Scholar]
  28. Smitskamp-Wilms E., Peters G. J., Pinedo H. M., van Ark-Otte J., Giaccone G. Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression. Biochem Pharmacol. 1994 Apr 20;47(8):1325–1332. doi: 10.1016/0006-2952(94)90330-1. [DOI] [PubMed] [Google Scholar]
  29. Stratford I. J., Adams G. E., Bremner J. C., Cole S., Edwards H. S., Robertson N., Wood P. J. Manipulation and exploitation of the tumour environment for therapeutic benefit. Int J Radiat Biol. 1994 Jan;65(1):85–94. doi: 10.1080/09553009414550121. [DOI] [PubMed] [Google Scholar]
  30. Wallin R., Gebhardt O., Prydz H. NAD(P)H dehydrogenase and its role in the vitamin K (2-methyl-3-phytyl-1,4-naphthaquinone)-dependent carboxylation reaction. Biochem J. 1978 Jan 1;169(1):95–101. doi: 10.1042/bj1690095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Walton M. I., Bibby M. C., Double J. A., Plumb J. A., Workman P. DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas. Eur J Cancer. 1992;28A(10):1597–1600. doi: 10.1016/0959-8049(92)90049-8. [DOI] [PubMed] [Google Scholar]
  32. Walton M. I., Smith P. J., Workman P. The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Commun. 1991 Jul;3(7):199–206. doi: 10.3727/095535491820873164. [DOI] [PubMed] [Google Scholar]
  33. Walton M. I., Sugget N., Workman P. The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys. 1992;22(4):643–647. doi: 10.1016/0360-3016(92)90495-4. [DOI] [PubMed] [Google Scholar]
  34. Workman P., Binger M., Kooistra K. L. Pharmacokinetics, distribution, and metabolism of the novel bioreductive alkylating indoloquinone EO9 in rodents. Int J Radiat Oncol Biol Phys. 1992;22(4):713–716. doi: 10.1016/0360-3016(92)90509-g. [DOI] [PubMed] [Google Scholar]
  35. Workman P. Bioreductive mechanisms. Int J Radiat Oncol Biol Phys. 1992;22(4):631–637. doi: 10.1016/0360-3016(92)90493-2. [DOI] [PubMed] [Google Scholar]
  36. Yao K. S., Clayton M., O'Dwyer P. J. Interaction of heat and hypoxia in modulating transcription of DT diaphorase in human colon adenocarcinoma cells. Cell Growth Differ. 1994 Feb;5(2):125–131. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES